Mohd Rizwan Jameel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohd Rizwan Jameel has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Aryan Kumar
2 shared publicationsJai Vardhan
2 shared publicationsPrem Shankar Mishra
2 shared publicationsShriram Sisodia
2 shared publications- Abdullah Khan
C.G. Bhakta Institute of Biotechnology, Uka Tarsadia University, Surat, India
1 shared publication Abhishek Sharma
1 shared publication
Latest Publications
- 19 June 2026
- Published by Elsevier
- p. 349-373
Emerging trends in immunogenetic research in type 2 diabetes mellitus (T2DM)
- 19 June 2026
- Published by Elsevier
- p. 349-373
Emerging trends in immunogenetic research in type 2 diabetes mellitus (T2DM)
- 19 June 2026
- Published by Elsevier
Contributors
- Open Access
- 30 December 2025
- Published by Neoplasia Research in Journal of Analytical Oncology
- Vol. 14, 96-105
Precision Reprogramming of Lung Cancer Biomarkers via CRISPR/Cas9: A Paradigm Shift in Personalized Immunotherapy
Lung cancer persists as the leading cause of cancer-related mortality globally, largely due to late detection, genomic complexity, and limited durability of existing therapeutic interventions. The integration of CRISPR/Cas9 gene-editing systems with biomarker-driven therapeutic strategies represents a transformative advance in precision oncology. Biomarkers—including genetic mutations, epigenetic alterations, protein signatures, and circulating analytes—enable early detection, patient stratification, and dynamic monitoring of therapeutic response. CRISPR/Cas9 offers a unique opportunity to directly reprogram these biomarkers or the pathways regulating them, enhancing tumor immunogenicity, reversing immune evasion mechanisms, and strengthening anti-tumor immune responses. Preclinical models demonstrate that CRISPR-mediated biomarker editing can restore antigen presentation, augment T-cell cytotoxicity, sensitize resistant tumors to immunotherapy, and improve tumor regression. Early clinical trials further validate the feasibility and safety of CRISPR-engineered immune cells in patients. However, major challenges persist, including off-target editing, inefficient delivery to solid tumors, tumor microenvironment–mediated suppression, and ethical considerations linked to genome manipulation. Rapid advancements in editing fidelity, lipid nanoparticle systems, viral vectors, engineered vesicles, high-throughput biomarker discovery, and artificial intelligence–assisted CRISPR design are expected to accelerate clinical translation. This review synthesizes the current landscape, mechanistic underpinnings, emerging applications, and future directions of CRISPR/Cas9-enabled biomarker engineering for lung cancer immunotherapy, positioning this technology as a cornerstone of next-generation personalized oncology.
- 30 December 2025
- Published by Neoplasia Research in Journal of Analytical Oncology
- Vol. 14, 96-105
Open AccessPrecision Reprogramming of Lung Cancer Biomarkers via CRISPR/Cas9: A Paradigm Shift in Personalized Immunotherapy
Lung cancer persists as the leading cause of cancer-related mortality globally, largely due to late detection, genomic complexity, and limited durability of existing therapeutic interventions. The integration of CRISPR/Cas9 gene-editing systems with biomarker-driven therapeutic strategies represents a transformative advance in precision oncology. Biomarkers—including genetic mutations, epigenetic alterations, protein signatures, and circulating analytes—enable early detection, patient stratification, and dynamic monitoring of therapeutic response. CRISPR/Cas9 offers a unique opportunity to directly reprogram these biomarkers or the pathways regulating them, enhancing tumor immunogenicity, reversing immune evasion mechanisms, and strengthening anti-tumor immune responses. Preclinical models demonstrate that CRISPR-mediated biomarker editing can restore antigen presentation, augment T-cell cytotoxicity, sensitize resistant tumors to immunotherapy, and improve tumor regression. Early clinical trials further validate the feasibility and safety of CRISPR-engineered immune cells in patients. However, major challenges persist, including off-target editing, inefficient delivery to solid tumors, tumor microenvironment–mediated suppression, and ethical considerations linked to genome manipulation. Rapid advancements in editing fidelity, lipid nanoparticle systems, viral vectors, engineered vesicles, high-throughput biomarker discovery, and artificial intelligence–assisted CRISPR design are expected to accelerate clinical translation. This review synthesizes the current landscape, mechanistic underpinnings, emerging applications, and future directions of CRISPR/Cas9-enabled biomarker engineering for lung cancer immunotherapy, positioning this technology as a cornerstone of next-generation personalized oncology.
- Open Access
Creation of Advance Construction of CRISPR-Cas9 via using Multi Round Gateway Cloning
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 (CRISPR-associated system) is used to edit specific genomic sequences with precision and efficacy. CRISPR/Cas9 system mediated double strand binding site through error-prone non homologous end joining repair in targeted sequences, which the deletion or insertion can be achieved by knock out gene. Creation advance construct of CRISPR/Cas9 of soluble starch synthase II-1, 2 and 3 ( SSSII ) genes in single destination binary vector through multi round LR reaction of Gateway technology. Gateway cloning system developed the suitable for the site-specific DNA recombination of lambda-bacteriophage and ccdB the cytotoxic protein, which is poisonous to most E. coli strains. A genetic transformation vector designed with appropriate gRNAs, Cas9, and antibiotic resistance was used to create SSSII knockout mutants.
Open AccessCreation of Advance Construction of CRISPR-Cas9 via using Multi Round Gateway Cloning
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 (CRISPR-associated system) is used to edit specific genomic sequences with precision and efficacy. CRISPR/Cas9 system mediated double strand binding site through error-prone non homologous end joining repair in targeted sequences, which the deletion or insertion can be achieved by knock out gene. Creation advance construct of CRISPR/Cas9 of soluble starch synthase II-1, 2 and 3 ( SSSII ) genes in single destination binary vector through multi round LR reaction of Gateway technology. Gateway cloning system developed the suitable for the site-specific DNA recombination of lambda-bacteriophage and ccdB the cytotoxic protein, which is poisonous to most E. coli strains. A genetic transformation vector designed with appropriate gRNAs, Cas9, and antibiotic resistance was used to create SSSII knockout mutants.
- Open Access
Erythrocyte ghosts and Plasma beads as Antigen peptide delivery systems in animals and humans
Erythrocytes are the most plentiful cells of the human body with desirable morphologic and physiologic characteristics and their function in drug delivery has been exploited comprehensively. These cellular carriers, containing significant biodegradability, biocompatibility, and duration in circulation, can be burdened by a wide spectrum of compounds of therapeutic interest Carrier erythrocytes holding drugs, enzymes or peptides, Cas, and Nanoparticles can be used as a delivery system that approval to changes in the kinetic behavior and selective bio-distribution of the substances encapsulated. Carrier erythrocytes have been exploited for numerous potential applications, including the intravenous slow release of drug targeting, therapeutic agents and enzyme therapy to a reticuloendothelial system (RES). Hypotonic dialysis is the process most usually utilized in the formation of erythrocytes of carrier, however many features concern the give up and the erythrocytes ghost characteristics obtained with this technique. Attempt was also completed observe but erythrocyte regular release entrapped substances/antigens with additional entrapment in the plasma beads, improves the protein immunogenicity. The glycoenzyme invertase of large molecular weight was utilized a model substance and entrapment of invertase consummate with the dialysis method. Enzyme entrapment was examined in derived erythrocytes from rabbits, goats and human. Intended for the immunological studies were used in the rabbits. Invertase entrapped erythrocytes rabbit, where point out was additional encapsulated in the plasma beads and a contrast of immunogenicity of lose invertase, entrapped invertase in erythrocytes and that entrapped in RBCs and additional in encapsulated the plasma beads were examined. Antibodies production was investigated are different periods such as 12, 20, 20 and 35 days.
Open AccessErythrocyte ghosts and Plasma beads as Antigen peptide delivery systems in animals and humans
Erythrocytes are the most plentiful cells of the human body with desirable morphologic and physiologic characteristics and their function in drug delivery has been exploited comprehensively. These cellular carriers, containing significant biodegradability, biocompatibility, and duration in circulation, can be burdened by a wide spectrum of compounds of therapeutic interest Carrier erythrocytes holding drugs, enzymes or peptides, Cas, and Nanoparticles can be used as a delivery system that approval to changes in the kinetic behavior and selective bio-distribution of the substances encapsulated. Carrier erythrocytes have been exploited for numerous potential applications, including the intravenous slow release of drug targeting, therapeutic agents and enzyme therapy to a reticuloendothelial system (RES). Hypotonic dialysis is the process most usually utilized in the formation of erythrocytes of carrier, however many features concern the give up and the erythrocytes ghost characteristics obtained with this technique. Attempt was also completed observe but erythrocyte regular release entrapped substances/antigens with additional entrapment in the plasma beads, improves the protein immunogenicity. The glycoenzyme invertase of large molecular weight was utilized a model substance and entrapment of invertase consummate with the dialysis method. Enzyme entrapment was examined in derived erythrocytes from rabbits, goats and human. Intended for the immunological studies were used in the rabbits. Invertase entrapped erythrocytes rabbit, where point out was additional encapsulated in the plasma beads and a contrast of immunogenicity of lose invertase, entrapped invertase in erythrocytes and that entrapped in RBCs and additional in encapsulated the plasma beads were examined. Antibodies production was investigated are different periods such as 12, 20, 20 and 35 days.
- Open Access
CRISPR/Cas9-Mediated Genome Editing of Soluble Starch Synthesis Enzyme in Rice for Low Glycemic Index
In the present study, the selected rice (Oryza sativa cv. indica) was genetically modified to increase the amylose content in the seeds. The ‘CRISPR-Cas9’ genome-editing tool was used to knock out three isoforms of soluble starch synthase (SSS) viz. SSSII-1, SSSII-2 and SSSII-3. A genetic transformation vector designed with appropriate gRNAs, Cas9, and antibiotic resistance was used to create SSS knockout mutants to enrich the content of amylose. Putative rice mutants were developed with high amylose content in the seeds of up to 63% as compared to 23% in the wild types (control). Rice with a low Glycemic Index (GI) value and high amylose content rice is preferred to avoid a sudden rise in glucose in the bloodstream. The frequencies of bi-allelic or homozygous transgenic lines of SSSII-1, SSSII-2, and SSSII-3 in the first generation were tested via the Mendelian fashion of segregated bi-allelic lines in the T1 generation of the putative rice mutants. The T1 generation segregation showed a frame-shift mutation. A molecular characterization of the putative mutants successfully demonstrated the development of a Cas9-free rice mutant with a higher amount of amylose in the rice.
Open AccessCRISPR/Cas9-Mediated Genome Editing of Soluble Starch Synthesis Enzyme in Rice for Low Glycemic Index
In the present study, the selected rice (Oryza sativa cv. indica) was genetically modified to increase the amylose content in the seeds. The ‘CRISPR-Cas9’ genome-editing tool was used to knock out three isoforms of soluble starch synthase (SSS) viz. SSSII-1, SSSII-2 and SSSII-3. A genetic transformation vector designed with appropriate gRNAs, Cas9, and antibiotic resistance was used to create SSS knockout mutants to enrich the content of amylose. Putative rice mutants were developed with high amylose content in the seeds of up to 63% as compared to 23% in the wild types (control). Rice with a low Glycemic Index (GI) value and high amylose content rice is preferred to avoid a sudden rise in glucose in the bloodstream. The frequencies of bi-allelic or homozygous transgenic lines of SSSII-1, SSSII-2, and SSSII-3 in the first generation were tested via the Mendelian fashion of segregated bi-allelic lines in the T1 generation of the putative rice mutants. The T1 generation segregation showed a frame-shift mutation. A molecular characterization of the putative mutants successfully demonstrated the development of a Cas9-free rice mutant with a higher amount of amylose in the rice.
- Open Access
- 31 May 2022
- Published by Biomedical Informatics in Bioinformation
- Vol. 18 (5) , 471-477
From design to validation of CRISPR/gRNA primers towards genome editing
Acinetobacter baumannii (AB) is one of the most common causes of nosocomial infections. Therefore, it is of interest to design and develop drugs against Acinetobacter baumannii. A strain of AB showing MIC 32 μg/ml against colistin was isolated from a hospital environment in Iran. Hence, we document data to glean insights from the molecular docking analysis of colistin with the PmrA protein from this bacterium.
- 31 May 2022
- Published by Biomedical Informatics in Bioinformation
- Vol. 18 (5) , 471-477
Open AccessFrom design to validation of CRISPR/gRNA primers towards genome editing
Acinetobacter baumannii (AB) is one of the most common causes of nosocomial infections. Therefore, it is of interest to design and develop drugs against Acinetobacter baumannii. A strain of AB showing MIC 32 μg/ml against colistin was isolated from a hospital environment in Iran. Hence, we document data to glean insights from the molecular docking analysis of colistin with the PmrA protein from this bacterium.